Stock listing
OTC:ADAPY Adaptimmune Therapeutics PLC Stock
Follow Adaptimmune Therapeutics PLC into a list and get an email when it puts out news.
Share price · OTC:ADAPY
$0.03 USD 0.00 (0.0%)
Close on Nov 20, 2026
- Day range
- $0.024 – $0.03 USDNov 20, 2026
- Volume
- 830,169 sharesNov 20, 2026
- Market cap
- $7.95M USDAt the close on Nov 20, 2026 · price × 265.1M shares outstanding
- 52-week range
- $0.0001 – $0.06 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $7,929 USDMedian day 167,400 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · OTC:ADAPY · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.03 | 0.00 | 0.0% | $0.024 | $0.03 | $0.024 | 830,169 | |
| $0.03 | +0.006 | +25.0% | $0.029 | $0.033 | $0.029 | 514,817 | |
| $0.024 | -0.008 | -25.0% | $0.023 | $0.035 | $0.021 | 433,300 | |
| $0.032 | -0.001 | -3.0% | $0.021 | $0.033 | $0.021 | 175,000 | |
| $0.033 | +0.003 | +10.0% | $0.03 | $0.033 | $0.021 | 1,255,000 | |
| $0.03 | +0.002 | +7.1% | $0.02 | $0.03 | $0.02 | 119,200 | |
| $0.028 | -0.002 | -6.7% | $0.013 | $0.03 | $0.013 | 166,700 | |
| $0.03 | +0.012 | +66.7% | $0.018 | $0.03 | $0.018 | 2,527,100 | |
| $0.018 | -0.007 | -28.0% | $0.018 | $0.025 | $0.018 | 246,200 | |
| $0.025 | +0.005 | +25.0% | $0.017 | $0.025 | $0.017 | 120,700 | |
| $0.02 | +0.001 | +5.3% | $0.017 | $0.025 | $0.017 | 168,000 | |
| $0.019 | -0.001 | -5.0% | $0.018 | $0.024 | $0.017 | 826,400 | |
| $0.02 | -0.005 | -20.0% | $0.03 | $0.03 | $0.018 | 79,000 | |
| $0.025 | -0.002 | -7.4% | $0.018 | $0.027 | $0.018 | 342,900 | |
| $0.027 | +0.004 | +17.4% | $0.021 | $0.028 | $0.02 | 289,600 | |
| $0.023 | -0.003 | -11.5% | $0.029 | $0.029 | $0.02 | 577,000 | |
| $0.026 | -0.003 | -10.3% | $0.029 | $0.029 | $0.025 | 144,700 | |
| $0.029 | 0.00 | 0.0% | $0.025 | $0.029 | $0.025 | 45,800 | |
| $0.029 | +0.004 | +16.0% | $0.025 | $0.03 | $0.025 | 43,800 | |
| $0.025 | -0.005 | -16.7% | $0.025 | $0.03 | $0.025 | 340,800 | |
| $0.03 | +0.005 | +20.0% | $0.032 | $0.032 | $0.025 | 42,000 | |
| $0.025 | -0.007 | -21.9% | $0.028 | $0.033 | $0.02 | 628,900 | |
| $0.032 | -0.001 | -3.0% | $0.028 | $0.033 | $0.028 | 187,700 | |
| $0.033 | -0.002 | -5.7% | $0.028 | $0.033 | $0.028 | 80,300 | |
| $0.035 | +0.003 | +9.4% | $0.02 | $0.035 | $0.02 | 58,700 | |
| $0.032 | -0.001 | -3.0% | $0.031 | $0.033 | $0.027 | 164,700 | |
| $0.033 | +0.003 | +10.0% | $0.028 | $0.037 | $0.022 | 558,300 | |
| $0.03 | +0.001 | +3.4% | $0.028 | $0.03 | $0.023 | 212,200 | |
| $0.029 | -0.001 | -3.3% | $0.028 | $0.03 | $0.028 | 108,000 | |
| $0.03 | 0.00 | 0.0% | $0.028 | $0.03 | $0.028 | 87,700 | |
| $0.03 | +0.002 | +7.1% | $0.026 | $0.032 | $0.026 | 77,400 | |
| $0.028 | 0.00 | 0.0% | $0.022 | $0.028 | $0.022 | 50,900 | |
| $0.028 | -0.001 | -3.4% | $0.022 | $0.029 | $0.02 | 137,000 | |
| $0.029 | -0.001 | -3.3% | $0.021 | $0.03 | $0.021 | 282,000 | |
| $0.03 | -0.007 | -18.9% | $0.02 | $0.037 | $0.02 | 221,400 | |
| $0.037 | -0.001 | -2.6% | $0.02 | $0.039 | $0.02 | 64,800 | |
| $0.038 | 0.00 | 0.0% | $0.04 | $0.04 | $0.027 | 229,500 | |
| $0.038 | +0.012 | +46.2% | $0.0010 | $0.039 | $0.0010 | 1,351,800 | |
| $0.026 | -0.001 | -3.7% | $0.018 | $0.027 | $0.018 | 93,800 | |
| $0.027 | +0.001 | +3.8% | $0.019 | $0.027 | $0.018 | 311,100 | |
| $0.026 | +0.003 | +13.0% | $0.019 | $0.026 | $0.019 | 123,100 | |
| $0.023 | -0.003 | -11.5% | $0.026 | $0.026 | $0.017 | 264,900 | |
| $0.026 | 0.00 | 0.0% | $0.026 | $0.026 | $0.023 | 44,500 | |
| $0.026 | -0.001 | -3.7% | $0.017 | $0.027 | $0.017 | 121,900 | |
| $0.027 | +0.004 | +17.4% | $0.02 | $0.027 | $0.02 | 452,300 | |
| $0.023 | 0.00 | 0.0% | $0.01 | $0.023 | $0.01 | 86,500 | |
| $0.023 | -0.002 | -8.0% | $0.025 | $0.025 | $0.018 | 69,900 | |
| $0.025 | 0.00 | 0.0% | $0.02 | $0.026 | $0.018 | 242,200 | |
| $0.025 | +0.001 | +4.2% | $0.018 | $0.027 | $0.018 | 228,700 | |
| $0.024 | +0.001 | +4.3% | $0.02 | $0.025 | $0.02 | 188,000 | |
| $0.023 | 0.00 | 0.0% | $0.02 | $0.026 | $0.02 | 94,500 | |
| $0.023 | -0.002 | -8.0% | $0.02 | $0.027 | $0.02 | 63,200 | |
| $0.025 | -0.001 | -3.8% | $0.026 | $0.026 | $0.021 | 222,700 | |
| $0.026 | -0.001 | -3.7% | $0.021 | $0.027 | $0.02 | 68,100 | |
| $0.027 | +0.001 | +3.8% | $0.022 | $0.027 | $0.021 | 92,700 | |
| $0.026 | +0.001 | +4.0% | $0.02 | $0.027 | $0.0050 | 82,900 | |
| $0.025 | -0.002 | -7.4% | $0.021 | $0.027 | $0.021 | 62,800 | |
| $0.027 | +0.004 | +17.4% | $0.02 | $0.027 | $0.02 | 212,300 | |
| $0.023 | -0.005 | -17.9% | $0.023 | $0.028 | $0.023 | 277,600 | |
| $0.028 | -0.001 | -3.4% | $0.029 | $0.029 | $0.023 | 276,500 | |
| $0.029 | +0.003 | +11.5% | $0.029 | $0.029 | $0.023 | 198,300 | |
| $0.026 | +0.001 | +4.0% | $0.024 | $0.029 | $0.024 | 166,800 | |
| $0.025 | -0.001 | -2.3% | $0.014 | $0.03 | $0.014 | 146,005 | |
| $0.026 | -0.001 | -5.2% | $0.027 | $0.03 | $0.026 | 246,249 | |
| $0.027 | 0.00 | 0.0% | $0.027 | $0.03 | $0.027 | 95,200 | |
| $0.027 | 0.00 | 0.0% | $0.025 | $0.029 | $0.025 | 156,000 |
- Ticker
- OTC:ADAPY
- Asset type
- Stock
- Exchange
- OTC
- Currency
- USD
Adaptimmune Therapeutics PLC on 6ix
- Calls
- 9 calls with a replay · 9 with a transcript · latest May 13, 2025
- Decks
- 10 decks · latest May 6, 2019
Valuation
balance Jun 30, 2025 · price Nov 20, 2026
- Enterprise value
- $7.57M USD
- P/E
- Not reported
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P 500
- -1.10
Forecasts
Analysts' consensus from EODHD, read Nov 11, 2026. Not 6ix's view and not investment advice.
- Price target
- 0.68 USD · Analysts' mean
- EPS, year to Dec 2025
- -0.47 · 1 analyst
Team and board
Officers
| Officer | Role |
|---|---|
| Christopher Hill | Chief Executive Officer and Chief Financial Officer |
Board
| Director | Role |
|---|---|
| Lawrence M. Alleva | Chairman and Non-Executive Director |
| Garry Menzel | Non-Executive Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Adaptimmune Therapeutics (OTC:ADAPY) Q1 2025 Earnings Call | Tue, May 13, 2025 · 9:00 AM ET | Replay |
| Adaptimmune Therapeutics (OTC:ADAPY) Q4 2024 Earnings Call | Thu, Mar 20, 2025 · 9:00 AM ET | Replay |
| Adaptimmune Therapeutics (OTC:ADAPY) Q3 2024 Earnings Call | Wed, Nov 13, 2024 · 9:00 AM ET | Replay |
| Adaptimmune Therapeutics (OTC:ADAPY) Q2 2024 Earnings Call | Mon, Aug 12, 2024 · 9:00 AM ET | Replay |
| Adaptimmune Therapeutics (OTC:ADAPY) Q1 2024 Earnings Call | Wed, May 15, 2024 · 9:00 AM ET | Replay |
| Adaptimmune Therapeutics (OTC:ADAPY) Q3 2021 Earnings Call | Thu, Nov 11, 2021 · 9:00 AM ET | Replay |
| Adaptimmune Therapeutics (OTC:ADAPY) Q2 2021 Earnings Call | Mon, Aug 09, 2021 · 4:30 PM ET | Replay |
| Adaptimmune Therapeutics (OTC:ADAPY) Q4 2020 Earnings Call | Thu, Feb 25, 2021 · 8:00 AM ET | Replay |
| Adaptimmune Therapeutics (OTC:ADAPY) Q3 2020 Earnings Call | Thu, Nov 05, 2020 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Quarter to Mar 31, 2026 | Apr 23, 2026 · After close | 0.0% |
| Quarter to Dec 31, 2025 | Mar 10, 2026 | +50.0% |
| Quarter to Sep 30, 2025 | Nov 28, 2025 | −5.1% |
| Q2 2025 | Aug 13, 2025 · Before open | +1.3% |
| Q1 2025 | May 13, 2025 | −7.8% |
| Q4 2024 | Mar 24, 2025 · After close | −9.8% |
| Q3 2024 | Nov 13, 2024 · After close | −23.4% |
| Q2 2024 | Aug 12, 2024 · Before open | +9.8% |
| Q1 2024 | May 15, 2024 | +4.3% |
| Q4 2023 | Mar 6, 2024 · Before open | +17.1% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q3 2023 | Nov 8, 2023 · Before open | −5.5% |
| Q2 2023 | Aug 9, 2023 · Before open | −1.2% |
| Q1 2023 | May 12, 2023 · After close | +1.5% |
| Q4 2022 | Mar 6, 2023 | −29.0% |
| Q3 2022 | Nov 8, 2022 · After close | +1.0% |
| Q2 2022 | Aug 4, 2022 · After close | +0.9% |
| Q1 2022 | May 9, 2022 · Before open | −9.9% |
| Q4 2021 | Mar 14, 2022 | −5.0% |
| Q3 2021 | Nov 4, 2021 · Before open | −4.0% |
| Q2 2021 | Aug 9, 2021 · After close | +3.5% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Corporate Update (May 2019) | Corporate update | 40 slides | May 6, 2019 |
| Technical Presentation (June 2017) | Technical | 13 slides | Jun 6, 2017 |
| Investor Presentation (April 2017) | Investor deck | 32 slides | Apr 10, 2017 |
| Investor Presentation (March 2017) | Investor deck | 31 slides | Mar 14, 2017 |
| J.P. Morgan Healthcare Conference 2017 | Conference | 40 slides | Jan 9, 2017 |
| Investor Presentation (December 2015) | Investor deck | 30 slides | Dec 15, 2015 |
| Jefferies Autumn Global Healthcare Conference 2015 | Conference | 42 slides | Nov 18, 2015 |
| Investor Presentation (November 2015) | Investor deck | 34 slides | Nov 18, 2015 |
| Investor Presentation (October 2015) | Investor deck | 32 slides | Oct 19, 2015 |
| Investor Presentation (September 2015) | Investor deck | 30 slides | Sep 15, 2015 |
IPO
Priced at US$17.00 an ADS on May 5, 2015.
- Price
- US$17.00 an ADS
- ADSs offered
- 11,250,000 American depositary shares
- Offering size
- US$191.3 million
- Underwriters' option
- Up to 1,687,500 more ADSs
- Listing
- ADAP on the Nasdaq Global Select Market
- Underwriters
- BofA Merrill Lynch, Cowen and Company, Leerink Partners, Guggenheim Securities · In the order on the cover
- ADSs delivered
- On or about May 11, 2015
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Feb 5, 2015 |
| Filed publicly | Apr 6, 2015 |
| Amended twice | Newest May 1, 2015 |
| Shares registered with an exchange | Apr 30, 2015 |
| Declared effective by the SEC | May 5, 2015 |
| Final prospectus, with the price | May 7, 2015 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | May 7, 2015 |
| CERTNAS · Nasdaq's certificate of listing | May 6, 2015 |
| EFFECT · Notice that a registration is effective | May 5, 2015 |
| F-1MEF · Registration of more shares for the same offering | May 5, 2015 |
| CORRESP · Letter to the SEC | May 1, 2015 |
| CORRESP · Letter to the SEC | May 1, 2015 |
| F-1/A · Registration statement, amended | May 1, 2015 |
| 8-A12B · Registration of shares for listing on an exchange | Apr 30, 2015 |
| CORRESP · Letter to the SEC | Apr 27, 2015 |
| F-1/A · Registration statement, amended | Apr 27, 2015 |
All 20 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Apr 22, 2015 |
| CORRESP · Letter to the SEC | Apr 17, 2015 |
| UPLOAD · Letter from the SEC | Apr 17, 2015 |
| CORRESP · Letter to the SEC | Apr 6, 2015 |
| F-1 · Registration statement | Apr 6, 2015 |
| UPLOAD · Letter from the SEC | Apr 1, 2015 |
| DRSLTR · Letter to the SEC with a draft | Mar 17, 2015 |
| DRS/A · Draft registration statement, amended | Mar 17, 2015 |
| UPLOAD · Letter from the SEC | Mar 4, 2015 |
| DRS · Draft registration statement | Feb 5, 2015 |
Open IPO · From the cover of the final prospectus (424B4) filed May 7, 2015
Financials
Annual, in USD
Income statement
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 178.0M | 60.3M | 27.1M | 6.15M | 3.96M | 1.12M | 59.5M | 37.8M | 14.2M | 9.87M |
| Cost of revenue | 70.0K | |||||||||
| Gross profit | 178.0M | |||||||||
| Research and development | 149.1M | 126.5M | 127.7M | 111.1M | 91.6M | 97.5M | 98.3M | 87.4M | 63.8M | 24.1M |
| Selling, general and administrative | 87.3M | 73.5M | 63.4M | |||||||
| Operating income | -68.8M | -139.7M | -164.0M | -162.2M | -133.4M | -139.8M | -82.4M | -80.7M | -72.8M | -24.6M |
| Depreciation and amortization | 10.8M | 9.45M | 5.27M | 5.63M | 6.63M | 7.17M | 7.19M | 5.03M | 3.13M | 705.0K |
| EBITDA | -57.9M | -130.3M | -158.7M | -156.6M | -126.8M | -132.6M | -75.2M | -75.6M | -69.7M | -23.9M |
| Interest expense | 3.35M | |||||||||
| Income before tax | -67.2M | -112.5M | -163.0M | -157.3M | -129.9M | -136.9M | -95.0M | -69.7M | -70.7M | -21.8M |
| Income tax | 3.58M | 1.34M | 2.50M | 791.0K | 162.0K | 242.0K | 497.0K | 451.0K | 892.0K | 244.0K |
| Net income | -70.8M | -113.9M | -165.5M | -158.1M | -130.1M | -137.2M | -95.5M | -70.1M | -71.6M | -22.1M |
| Earnings per share, basic | -0.05 | -0.09 | -0.17 | -0.17 | -0.15 | -0.22 | -0.16 | -0.13 | -0.17 | -0.17 |
| Earnings per share, diluted | -0.05 | -0.09 | -0.17 | -0.17 | -0.15 | -0.22 | -0.16 | -0.13 | -0.17 | -0.17 |
Balance sheet
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 91.1M | 144.0M | 108.0M | 149.9M | 56.9M | 50.4M | 68.4M | 84.0M | 158.8M | 229.0M |
| Short-term investments | 60.5M | 2.95M | 96.6M | 219.6M | 311.3M | 39.1M | 136.8M | 124.2M | ||
| Receivables | 1.45M | 821.0K | 7.43M | 752.0K | 139.0K | 192.0K | 206.0K | 1.48M | 4.00K | |
| Inventory | 7.32M | |||||||||
| Current assets | 188.2M | 207.6M | 255.4M | 415.5M | 398.2M | 120.5M | 231.1M | 230.2M | 198.8M | 295.1M |
| Property, plant and equipment | 31.3M | 50.9M | 53.5M | 30.5M | 27.8M | 31.1M | 36.1M | 40.7M | 27.9M | 5.39M |
| Total assets | 246.0M | 282.6M | 328.9M | 469.5M | 451.1M | 181.5M | 276.7M | 281.1M | 234.5M | 300.7M |
| Accounts payable | 8.69M | 8.13M | 4.75M | 8.11M | 6.39M | 6.36M | 4.08M | 8.38M | 11.3M | 1.98M |
| Current liabilities | 64.5M | 72.8M | 64.5M | 62.5M | 39.1M | 34.3M | 24.4M | 74.3M | 40.3M | 26.8M |
| Long-term debt | 50.2M | |||||||||
| Total debt | 54.3M | |||||||||
| Total liabilities | 234.1M | 243.1M | 247.0M | 263.6M | 109.9M | 57.9M | 29.9M | 78.2M | 68.4M | 41.6M |
| Shareholders' equity | 11.8M | 39.5M | 81.9M | 206.0M | 341.2M | 123.6M | 246.9M | 203.0M | 166.1M | 259.0M |
| Shares outstanding | 1.54B | 1.36B | 987.1M | 928.5M | 928.8M | 631.0M | 627.5M | 562.1M | 424.8M | 424.7M |
Cash flow
| Line | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -73.2M | -140.9M | -141.8M | 10.7M | -53.6M | -112.5M | -104.4M | -54.3M | -48.2M | -29.7M |
| Capital spending | -886.0K | -4.68M | -29.5M | -8.57M | -2.34M | -1.59M | -3.91M | -24.6M | -11.5M | -5.08M |
| Free cash flow | -74.1M | -145.6M | -171.3M | 2.15M | -55.9M | -114.1M | -108.3M | -79.0M | -59.7M | -34.7M |
| Cash from investing | -59.0M | 176.5M | 89.1M | 75.8M | -278.9M | 94.9M | -17.5M | -126.1M | 17.8M | -58.8M |
| Cash from financing | 78.7M | 880.0K | 12.9M | 3.29M | 340.1M | 366.0K | 102.7M | 103.6M | 17.0K | 274.9M |
| Change in cash | -53.8M | 37.4M | -42.1M | 90.2M | 6.58M | -17.6M | -15.8M | -74.5M | -36.0M | 177.9M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| RW · Request to withdraw a registration | Apr 22, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 17, 2026 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Nov 17, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| 424B3 · Prospectus | Nov 13, 2025 | Offer document | SEC |
| 15-12G | Nov 13, 2025 | Other filings | SEC |
| S-8 POS | Oct 28, 2025 | Offer document | SEC |
| S-8 POS | Oct 28, 2025 | Offer document | SEC |
| S-8 POS | Oct 28, 2025 | Offer document | SEC |
| POS AM · Amendment to an effective registration | Oct 28, 2025 | Offer document | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 25 | Oct 28, 2025 | Other filings | SEC |
| 8-K · Current report | Oct 20, 2025 | Current report | SEC |
| 3 · Initial statement of ownership | Oct 8, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 26, 2025 | Current report | SEC |
| 8-K · Current report | Sep 12, 2025 | Current report | SEC |
| 8-K · Current report | Sep 8, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Sep 3, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 2, 2025 | Other filings | SEC |
| 4 · Change in ownership | Aug 29, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 29, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 29, 2025 | Management or board change | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| SCHEDULE 13D/A · Big-stake notice, amended | Aug 19, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 19, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Aug 15, 2025 | Management or board change | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 15, 2025 | Other filings | SEC |
| 8-K · Current report | Aug 14, 2025 | Current report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Aug 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 13, 2025 | Results | SEC |
| 8-K · Current report | Aug 7, 2025 | Management or board change | SEC |
| 8-K · Current report | Jul 31, 2025 | Acquisition or disposal | SEC |
| 4 · Change in ownership | Jul 30, 2025 | Insider trade | SEC |
| 8-K · Current report | Jul 28, 2025 | Material contract | SEC |
| 8-K · Current report | Jul 17, 2025 | Current report | SEC |
| 8-K · Current report | May 29, 2025 | Meeting outcome | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2025 | Big-stake notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 8-K · Current report | May 1, 2025 | Current report | SEC |
| ARS · Annual report to shareholders | Apr 25, 2025 | Annual report | SEC |
| DEF 14A · Proxy statement | Apr 25, 2025 | Meeting notice | SEC |
| S-3 · Registration statement | Apr 18, 2025 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Apr 15, 2025 | Meeting notice | SEC |
| 8-K · Current report | Apr 14, 2025 | Management or board change | SEC |
| 10-K · Annual report | Mar 24, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 24, 2025 | Material contract | SEC |
| 8-K · Current report | Mar 20, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 20, 2025 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 12, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 11, 2025 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 17, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 17, 2025 | Other filings | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 15, 2025 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jan 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 15, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Jan 15, 2025 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 8, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Dec 19, 2024 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Dec 5, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 13, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 13, 2024 | Results | SEC |
| 8-K · Current report | Nov 13, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 13, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Nov 1, 2024 | Current report | SEC |
| 8-K · Current report | Sep 23, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 8-K · Current report | Aug 2, 2024 | Current report | SEC |
| 8-K · Current report | Jul 16, 2024 | Management or board change | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jul 1, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 18, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 11, 2024 | Management or board change | SEC |
| 8-K · Current report | May 30, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | May 15, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 15, 2024 | Results | SEC |
| 8-K · Current report | May 15, 2024 | Material contract | SEC |
| 8-K · Current report | May 14, 2024 | Meeting outcome | SEC |
| ARS · Annual report to shareholders | Apr 22, 2024 | Annual report | SEC |
| 8-K · Current report | Apr 12, 2024 | Current report | SEC |
| DEF 14A · Proxy statement | Apr 11, 2024 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Apr 2, 2024 | Big-stake notice | SEC |
| PRE 14A · Preliminary proxy statement | Apr 1, 2024 | Meeting notice | SEC |
| 3 · Initial statement of ownership | Mar 26, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Mar 26, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 18, 2024 | Insider trade | SEC |
| 10-K · Annual report | Mar 6, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2024 | Results | SEC |
| 8-K · Current report | Feb 27, 2024 | Management or board change | SEC |
| 8-K · Current report | Feb 16, 2024 | Current report | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Jan 31, 2024 | Current report | SEC |
| SC 13G · Big-stake notice | Jan 30, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 29, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 17, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 12, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 4, 2024 | Current report | SEC |
| 8-K · Current report | Dec 6, 2023 | Current report | SEC |
| S-8 · Registration statement for employee plans | Nov 30, 2023 | Offer document | SEC |
| 8-K · Current report | Nov 14, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| SC 13G · Big-stake notice | Nov 8, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Nov 8, 2023 | Results | SEC |
| 8-K · Current report | Nov 3, 2023 | Management or board change | SEC |
| 3 · Initial statement of ownership | Nov 1, 2023 | Insider trade | SEC |
| 8-K · Current report | Oct 31, 2023 | Current report | SEC |
| 4 · Change in ownership | Sep 1, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 31, 2023 | Current report | SEC |
| 8-K/A · Current report, amended | Aug 10, 2023 | Current report | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 9, 2023 | Results | SEC |
| 4 · Change in ownership | Aug 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jul 10, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jul 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 5, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 3, 2023 | Insider trade | SEC |
| S-8 POS | Jun 29, 2023 | Offer document | SEC |
| S-8 POS | Jun 29, 2023 | Offer document | SEC |
| 8-K · Current report | Jun 29, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Jun 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 1, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 1, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 1, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 1, 2023 | Acquisition or disposal | SEC |
| 425 | May 30, 2023 | Other filings | SEC |
| 8-K · Current report | May 30, 2023 | Meeting outcome | SEC |
| 425 | May 22, 2023 | Other filings | SEC |
| 8-K · Current report | May 22, 2023 | Current report | SEC |
| 8-K · Current report | May 16, 2023 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 12, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2023 | Results | SEC |
| EFFECT · Notice that a registration is effective | Apr 21, 2023 | Other filings | SEC |
| 424B3 · Prospectus | Apr 20, 2023 | Offer document | SEC |
| CORRESP · Letter to the SEC | Apr 18, 2023 | Other filings | SEC |
| S-4/A · Registration statement, amended | Apr 18, 2023 | Offer document | SEC |
| DEF 14A · Proxy statement | Apr 13, 2023 | Meeting notice | SEC |
| 8-K · Current report | Apr 11, 2023 | Material contract | SEC |
| UPLOAD · Letter from the SEC | Apr 6, 2023 | Other filings | SEC |
| S-4 · Registration statement | Apr 5, 2023 | Offer document | SEC |
| PRE 14A · Preliminary proxy statement | Apr 3, 2023 | Meeting notice | SEC |
| SC 13D/A · Big-stake notice, amended | Mar 30, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Mar 10, 2023 | Current report | SEC |
| 425 | Mar 9, 2023 | Other filings | SEC |
| 425 | Mar 9, 2023 | Other filings | SEC |
| 10-K · Annual report | Mar 6, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 6, 2023 | Results | SEC |
| 425 | Mar 6, 2023 | Other filings | SEC |
| 8-K · Current report | Mar 6, 2023 | Material contract | SEC |
This page holds 200 of 808 filings. Open Filings
Cap table
Built by 6ix from Adaptimmune Therapeutics PLC’s releases
- Common shares
- 265,051,591
- Fully diluted
- 265,051,591
Fully diluted
| Line | Shares |
|---|---|
| Common shares | 265,051,591 |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 265,051,591 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Ali Behbahani Other companies: SpyGlass Pharma, Inc. (Director · Since at least Feb 5, 2026); NeueHealth Inc (Director · Since at least Oct 2, 2025); Korro Bio, Inc. (Director · Since at least Nov 3, 2023); Arcellx Inc (Director · Since at least Feb 3, 2022); Monte Rosa Therapeutics, Inc. (Director · Since at least Jun 23, 2021); Nkarta, Inc. (Director · Since at least Jul 9, 2020); Black Diamond Therapeutics, Inc. (Director · Since at least Jan 29, 2020); CRISPR Therapeutics AG (Director · Since at least Jun 11, 2019); Minerva Surgical, Inc. (Director · Oct 21, 2021 – Jun 10, 2022 · Past); CVRx, Inc. (Director · Jun 29, 2021 – Jun 4, 2024 · Past); Oyster Point Pharma Inc (Director · Oct 30, 2019 – Jan 3, 2023 · Past) | Director · Since at least Jul 2, 2019 |
| Garry E. Menzel Other companies: Stoke Therapeutics, Inc. (Director · Since at least Aug 13, 2020); Black Diamond Therapeutics, Inc. (Operating Partner, GHO Capital Partners LLP · Since at least Jan 29, 2020); Tcr2 Therapeutics Inc (President and CEO, Director · Feb 13, 2019 – Jun 1, 2023 · Past); DaVita Inc. (Senior Vice President, Finance · Sep 9, 2013 – Sep 9, 2013 · Past); Regulus Therapeutics Inc (COO & Executive VP, Finance · Oct 4, 2012 – Dec 11, 2012 · Past) | Non-Executive Director · Since at least Jun 1, 2023 |
| Lawrence M. Alleva Other companies: Galera Therapeutics, Inc. (Director · Since at least Nov 6, 2019); Mersana Therapeutics Inc (Director · Since at least Sep 5, 2017); Bright Horizons Family Solutions Inc. (Board Member · Since at least May 12, 2016); Tesaro Inc (Director · Jun 1, 2016 – Jan 22, 2019 · Past); Synlogic Inc (Director · Sep 30, 2015 – Jun 29, 2016 · Past) | Chairman and Non-Executive Director · Since at least Jan 1, 2016 |
| Charles Elliott Sigal Other companies: Alnylam Pharmaceuticals, Inc. (Director · Since at least Aug 22, 2022); Vir Biotechnology, Inc. (Director · Since at least Jul 10, 2020); Surface Oncology Inc (Director · Apr 18, 2018 – Sep 8, 2023 · Past) | Director · Jan 1, 2016 – Jul 3, 2023 · Past |
| Rafael G. Amado Other companies: Zai Lab Ltd. (President, Head of Global Research and Development · Since at least Dec 30, 2022); Poseida Therapeutics Inc (Director · Apr 13, 2023 – Jan 8, 2025 · Past); Allogene Therapeutics, Inc. (EVP of R&D · Sep 3, 2019 – Oct 7, 2022 · Past) | President, R&D · Jan 1, 2016 – Aug 6, 2019 · Past |
| Adrian Rawcliffe Other companies: Wave Life Sciences Ltd. (CEO-Partner and Chief Executive Officer · Since at least Feb 1, 2017); Human Genome Sciences Inc (Chief Financial Officer, Director · Jul 30, 2012 – Jul 30, 2012 · Past) | Chief Executive Officer, Director · Jan 1, 2016 – Feb 20, 2025 · Past |
| Helen Tayton-Martin Other companies: Evaxion A/S (Chief Executive Officer · Since at least Mar 18, 2026); Trillium Therapeutics Inc (Director · Jan 1, 2021 – Nov 17, 2021 · Past) | Chief Business & Strgy Officer · Jan 1, 2016 – Jan 15, 2024 · Past |
| James Noble Other companies: LAVA Therapeutics NV (Director · Since at least Jan 1, 2025); GW Pharmaceuticals plc (Director · Oct 1, 2018 – May 5, 2021 · Past) | Director · Jan 1, 2016 – Jul 1, 2022 · Past |
| Michael Garone Other companies: Immunomedics Inc (Chief Financial Officer · Jun 27, 2016 – Jul 3, 2017 · Past); Emisphere Technologies Inc (CFO · Mar 12, 2009 – Jan 14, 2016 · Past) | Interim CFO · Oct 1, 2019 – Oct 1, 2019 · Past |
| Cintia Piccina Other companies: Autolus Therapeutics plc (U.S. CCO & Country Gen Manager · Since at least Mar 18, 2026) | Chief Commercial Officer · Mar 18, 2024 – Feb 20, 2025 · Past |
All 14 people
| Person | Seat |
|---|---|
| Gavin Wood Other companies: Affymetrix Inc (EVP, Chief Financial Officer · May 20, 2013 – Mar 31, 2016 · Past) | Chief Financial Officer · Since at least Apr 1, 2020 |
| William C Bertrand Jr Other companies: Ardelyx, Inc. (Director · Since at least Jun 2, 2016) | Chief Operating Officer · Since at least Mar 15, 2017 |
| Christopher Hill | Chief Executive Officer and Chief Financial Officer · Since at least Nov 5, 2026 |
| Joanna Elizabeth Brewer | Chief Scientific Officer · May 4, 2022 – Feb 20, 2025 · Past |
Log in to ask 6ix AI your own questions about Adaptimmune Therapeutics PLC.